AT-07 A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL

BACKGROUND: Ependymoma is an uncommon primary CNS tumor in adults, with no standardized treatment at recurrence. Little is known of the symptom burden associated with potential treatments. CERN-0802 combined lapatinib (targets ErbB1, ErbB2) with dose-dense temozolomide for patients with recurrent di...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Armstrong, Terri S., Vera-Bolanos, Elizabeth, Gilbert, Mark, Yuan, Ying, Wani, Khalida, Wu, Jimin, Omuro, Antonio, Lieberman, Frank, Robins, H. Ian, Gerstner, Elizabeth, Wu, Jing, Wen, Patrick, Mikkelsen, Tom, Aldape, Ken, Mendoza, Tito
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2014
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217844/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires